EFFECTIVENESS OF SUPERVISED, INTERMITTENT THERAPY FOR TUBERCULOSIS IN HIV-INFECTED PATIENTS

被引:88
作者
ALWOOD, K
KERULY, J
MOORERICE, K
STANTON, DL
CHAULK, CP
CHAISSON, RE
机构
[1] JOHNS HOPKINS UNIV, SCH MED, AIDS SERV, BALTIMORE, MD 21205 USA
[2] BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA
关键词
HIV; TUBERCULOSIS; DIRECTLY OBSERVED THERAPY; SURVIVAL;
D O I
10.1097/00002030-199408000-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate the effectiveness of supervised therapy for tuberculosis (TB) in patients with HIV infection. Design: Retrospective, chart review. Patients: Patients with TB and HIV infection. Setting: Urban, public TB clinic. Main measures and results: A total of 107 patients with TB and HIV infection were studied. Most were men (78%), African American (91%), uninsured or on Medicaid (88%), and 67% were injecting drug users. TB was diagnosed before AIDS in 31% of subjects, at the time of AIDS in 32%, and after AIDS in 37%. Clinical features varied by stage of HIV disease. Sixteen patients received no therapy and died before TB was diagnosed, 10 died during the first 8 weeks of treatment. Seventy-eight patients received > 8 weeks therapy, of whom 48 (62%) were given directly observed therapy twice weekly and 30 (38%) received self-administered daily therapy. Patients who received directly observed therapy were more likely to complete 6 months of therapy (96 versus 76%, P = 0.02) and more likely to survive after therapy ended (85 versus 57%, P = 0.01). By logistic regression, directly observed therapy, AIDS diagnosed before TB, and age were significantly associated with survival outcome. Conclusion: Directly observed therapy for TB in patients with HIV infection is highly effective and associated with better adherence to therapy and survival.
引用
收藏
页码:1103 / 1108
页数:6
相关论文
共 30 条
  • [1] ALLAN WGL, 1982, TUBERCLE, V63, P89
  • [2] 2-YEAR INCIDENCE OF TUBERCULOSIS IN COHORTS OF HIV-INFECTED AND UNINFECTED URBAN RWANDAN WOMEN
    ALLEN, S
    BATUNGWANAYO, J
    KERLIKOWSKE, K
    LIFSON, AR
    WOLF, W
    GRANICH, R
    TAELMAN, H
    VANDEPERRE, P
    SERUFILIRA, A
    BOGAERTS, J
    SLUTKIN, G
    HOPEWELL, PC
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (06): : 1439 - 1444
  • [3] BASS J, 1992, AM REV RESPIR DIS, V146, P1623
  • [4] BASS JB, 1990, AM REV RESPIR DIS, V142, P725
  • [5] TUBERCULOSIS - COMMENTARY ON A REEMERGENT KILLER
    BLOOM, BR
    MURRAY, CJL
    [J]. SCIENCE, 1992, 257 (5073) : 1055 - 1064
  • [6] RESURGENT TUBERCULOSIS IN NEW-YORK-CITY - HUMAN-IMMUNODEFICIENCY-VIRUS, HOMELESSNESS, AND THE DECLINE OF TUBERCULOSIS-CONTROL PROGRAMS
    BRUDNEY, K
    DOBKIN, J
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (04): : 745 - 749
  • [7] CDC, 1993, MMWR-MORBID MORTAL W, V42, P1
  • [8] TUBERCULOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - CLINICAL-FEATURES, RESPONSE TO THERAPY, AND SURVIVAL
    CHAISSON, RE
    SCHECTER, GF
    THEUER, CP
    RUTHERFORD, GW
    ECHENBERG, DF
    HOPEWELL, PC
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (03): : 570 - 574
  • [9] A 62-DOSE, 6-MONTH THERAPY FOR PULMONARY AND EXTRAPULMONARY TUBERCULOSIS - A TWICE-WEEKLY, DIRECTLY OBSERVED, AND COST-EFFECTIVE REGIMEN
    COHN, DL
    CATLIN, BJ
    PETERSON, KL
    JUDSON, FN
    SBARBARO, JA
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) : 407 - 415
  • [10] USPHS TUBERCULOSIS SHORT-COURSE CHEMOTHERAPY TRIAL-21 - EFFECTIVENESS, TOXICITY, AND ACCEPTABILITY - THE REPORT OF FINAL RESULTS
    COMBS, DL
    OBRIEN, RJ
    GEITER, LJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) : 397 - 406